DK0853627T3 - Substituerede liposaccharider, som er egnede til behandling og forebyggelse af endotoksæmi - Google Patents

Substituerede liposaccharider, som er egnede til behandling og forebyggelse af endotoksæmi

Info

Publication number
DK0853627T3
DK0853627T3 DK96923234T DK96923234T DK0853627T3 DK 0853627 T3 DK0853627 T3 DK 0853627T3 DK 96923234 T DK96923234 T DK 96923234T DK 96923234 T DK96923234 T DK 96923234T DK 0853627 T3 DK0853627 T3 DK 0853627T3
Authority
DK
Denmark
Prior art keywords
endotoxemia
treatment
prevention
liposaccharides
substituted liposaccharides
Prior art date
Application number
DK96923234T
Other languages
Danish (da)
English (en)
Inventor
J Christ William
P Rossignol Daniel
Seiichi Kobayashi
Tsutomu Kawata
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23833509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0853627(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DK0853627T3 publication Critical patent/DK0853627T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK96923234T 1995-06-05 1996-06-05 Substituerede liposaccharider, som er egnede til behandling og forebyggelse af endotoksæmi DK0853627T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/461,675 US5750664A (en) 1995-06-05 1995-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia
PCT/US1996/009578 WO1996039411A1 (en) 1995-06-05 1996-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Publications (1)

Publication Number Publication Date
DK0853627T3 true DK0853627T3 (da) 2004-06-01

Family

ID=23833509

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96923234T DK0853627T3 (da) 1995-06-05 1996-06-05 Substituerede liposaccharider, som er egnede til behandling og forebyggelse af endotoksæmi

Country Status (21)

Country Link
US (8) US5681824A (de)
EP (1) EP0853627B1 (de)
JP (3) JP4009318B2 (de)
KR (1) KR100416335B1 (de)
CN (1) CN1067082C (de)
AT (1) ATE258185T1 (de)
AU (1) AU707779C (de)
CA (1) CA2223140C (de)
DE (1) DE69631376T2 (de)
DK (1) DK0853627T3 (de)
ES (1) ES2214543T3 (de)
HU (1) HU221342B1 (de)
IL (2) IL122251A0 (de)
MX (1) MX9709502A (de)
NO (1) NO310239B1 (de)
NZ (1) NZ312299A (de)
PT (1) PT853627E (de)
RU (1) RU2170738C2 (de)
TW (1) TW366345B (de)
WO (1) WO1996039411A1 (de)
ZA (1) ZA964666B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
CN1150001C (zh) * 1996-07-03 2004-05-19 卫材株式会社 含有脂质a类似物的注射剂及其制备方法
EP1111390A4 (de) * 1998-09-01 2007-11-14 Eisai R&D Man Co Ltd Verfahren zum einschätzen von lipidanalog enthaltenden injektionen
WO2000041703A1 (en) 1999-01-14 2000-07-20 Eisai Co., Ltd. Administration of an anti-endotoxin drug by intravenous infusion
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
CZ20012919A3 (cs) 1999-02-10 2002-03-13 Sankyo Company, Limited Analogy etherového typu lipidu A 1-karboxylové kyseliny
AU2001229479A1 (en) * 2000-01-14 2001-07-24 Eisai Co. Ltd. Prevention and treatment of endotoxemia and related complications associated with surgery
US20050101549A1 (en) * 2000-01-14 2005-05-12 Melvyn Lynn Prevention and treatment of endotoxemia and related complications associated with surgery
AU2001238507C9 (en) 2000-02-18 2005-07-07 Eisai R&D Management Co., Ltd. Micelles
US6861512B2 (en) 2000-03-01 2005-03-01 Eisai Co., Ltd. Separation of olefinic isomers
US20030105033A1 (en) * 2000-06-09 2003-06-05 Rossignol Daniel P. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
US20020042379A1 (en) * 2000-06-09 2002-04-11 Daniel Rossignol Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
WO2002088072A1 (fr) * 2001-04-23 2002-11-07 Eisai Co., Ltd. Procede de preparation de composes d'alkylene
WO2002088062A1 (fr) * 2001-04-23 2002-11-07 Eisai Co., Ltd. Procede de preparation de derives d'alcool
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
WO2002094019A1 (en) * 2001-05-22 2002-11-28 Eisai Co., Ltd Highly purified antiendotoxin compound
DE10125179A1 (de) * 2001-05-23 2002-12-05 Laves Ralph Georg Verwendung von LPS zur Behandlung intestinaler Entzündungsprozesse
EP1420798A4 (de) * 2001-08-10 2007-07-25 Eisai Co Ltd Behandlung und prävention von erkrankungen und zuständen im zusammenhang mit hitzeschock-protein
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
US6913888B2 (en) * 2001-12-11 2005-07-05 Duke University Toll-like receptor 4 mutations
AU2002950657A0 (en) * 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
WO2004058788A1 (ja) * 2002-12-24 2004-07-15 Sankyo Company, Limited 右糖グルコースリピドa類縁体
SI1589934T1 (sl) * 2003-01-06 2016-02-29 Corixa Corporation Corporation Service Company Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
US7906633B2 (en) * 2003-02-20 2011-03-15 Eisai R&D Management Co., Ltd. Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof
MXPA05009428A (es) * 2003-03-05 2005-12-12 Eisai Co Ltd Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2005027826A2 (en) * 2003-07-14 2005-03-31 Eisai, Co, Ltd. Methods and treating severe acute respiratory syndrome
WO2005072097A2 (en) 2003-12-16 2005-08-11 University Of Massachusetts Toll-like receptor 9 modulators
WO2005066193A1 (ja) * 2004-01-08 2005-07-21 Sankyo Company, Limited 左糖グルコースリピドa類縁体
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
KR101205064B1 (ko) 2005-04-26 2012-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 암 면역요법을 위한 조성물과 방법
WO2006138681A2 (en) * 2005-06-17 2006-12-28 University Of Rochester Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion
JP5118968B2 (ja) * 2005-08-31 2013-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 リピッドａ類縁体の製造方法
KR101382162B1 (ko) * 2005-08-31 2014-04-07 에자이 알앤드디 매니지먼트 가부시키가이샤 리피드 ａ 유사체의 제조 방법
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
US20100152429A1 (en) 2006-11-22 2010-06-17 Eisai R&D Management Co., Ltd. Sodium salt of disaccharide compound, method for producing the same, and use of the same
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
CA2670124C (en) 2006-11-23 2015-04-21 Cadila Pharmaceuticals Limited Poly-tlr antagonist
US20110201569A1 (en) * 2009-09-16 2011-08-18 Heidi Ehrentraut Methods For Treating Myocardial Disorders
WO2011038537A1 (zh) * 2009-09-29 2011-04-07 上海南方基因科技有限公司 败血症以及败血症休克的预测、预防和治疗方法及试剂盒
GB201013785D0 (en) 2010-08-17 2010-09-29 Ucl Business Plc Treatment
JP2012246470A (ja) 2011-05-31 2012-12-13 Sharp Corp 半導体ナノ粒子の製造方法、半導体ナノ粒子、ならびにこれを用いた蛍光体
US9115097B2 (en) * 2011-12-22 2015-08-25 Nanoco Technologies Ltd. Surface modified nanoparticles
US9132141B2 (en) 2012-03-28 2015-09-15 University Of Maryland, Baltimore Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections
WO2014113048A1 (en) * 2013-01-18 2014-07-24 Loma Linda University Compositions and methods for diagnosing and treating sepsis
US10808246B2 (en) 2013-07-11 2020-10-20 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
US9584991B1 (en) * 2014-06-19 2017-02-28 Isaac S. Daniel Method of communicating and accessing social networks using interactive coded messages
KR102306956B1 (ko) * 2016-03-30 2021-10-01 아유비스 리서치, 인코포레이티드 신규한 조성물 및 치료 방법
EP3795576B1 (de) * 2016-09-14 2023-06-07 Genomatica, Inc. 1,3-fettdiolverbindungen und deren glykolysierten derivate
EP3512508B1 (de) 2016-09-16 2022-03-16 Eisai R&D Management Co., Ltd. Verfahren zur verwendung von eritoran als tlr4-antagonist zur behandlung von ebola und morbus marburg
JP7487187B2 (ja) * 2018-12-17 2024-05-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソームを含む製剤
WO2021207218A1 (en) 2020-04-06 2021-10-14 Eisai R&D Management Co., Ltd. Treatment of nidovirales infection with eritoran
CN113527396B (zh) * 2020-04-17 2024-02-02 上海医药工业研究院 一种疫苗佐剂mpla的中间体、合成及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495346A (en) * 1981-03-30 1985-01-22 Wisconsin Alumni Research Foundation Method of preparing a disaccharide
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
JPS6153295A (ja) * 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
NL8601551A (nl) * 1985-06-28 1987-01-16 Sandoz Ag Nieuwe saccharides, hun bereiding en farmaceutische samenstellingen, die hen bevatten.
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
JP2839916B2 (ja) * 1989-10-20 1998-12-24 三共株式会社 リピドａ３位エーテル類縁体
PT94481B (pt) 1989-12-11 1997-02-28 Sankyo Co Processo para a preparacao de analogos de lipidos a tendo imunoactividade e actividade anti-tumoral
JP2847319B2 (ja) 1990-05-18 1999-01-20 イビデン株式会社 電子部品搭載用多層ボンディング基板
JP3040847B2 (ja) 1990-06-22 2000-05-15 三共株式会社 リピドｘ類縁体
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
JP3135990B2 (ja) 1992-07-31 2001-02-19 沖電気工業株式会社 パリティ付加回路
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
US5681824A (en) 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6417172B1 (en) 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
JP4235193B2 (ja) 2005-06-07 2009-03-11 日本電信電話株式会社 イベント履歴蓄積装置、イベント情報検証装置、イベント履歴蓄積方法、イベント情報検証方法およびイベント情報処理システム

Also Published As

Publication number Publication date
JP2007269812A (ja) 2007-10-18
CA2223140C (en) 2008-08-05
KR19990022104A (ko) 1999-03-25
US5935938A (en) 1999-08-10
JP4009318B2 (ja) 2007-11-14
NZ312299A (en) 1999-08-30
WO1996039411A1 (en) 1996-12-12
NO310239B1 (no) 2001-06-11
HUP9802662A3 (en) 1999-06-28
US20030144503A1 (en) 2003-07-31
US5681824A (en) 1997-10-28
AU707779C (en) 2001-12-06
EP0853627A1 (de) 1998-07-22
US20080214802A1 (en) 2008-09-04
DE69631376T2 (de) 2004-11-11
NO975644L (no) 1998-02-04
ZA964666B (en) 1997-03-11
MX9709502A (es) 1998-10-31
US7737129B2 (en) 2010-06-15
RU2170738C2 (ru) 2001-07-20
AU6380296A (en) 1996-12-24
DE69631376D1 (de) 2004-02-26
NO975644D0 (no) 1997-12-04
EP0853627A4 (de) 1998-10-07
JPH11506793A (ja) 1999-06-15
AU707779B2 (en) 1999-07-22
TW366345B (en) 1999-08-11
US5750664A (en) 1998-05-12
CN1067082C (zh) 2001-06-13
HU221342B1 (en) 2002-09-28
ES2214543T3 (es) 2004-09-16
US7994154B2 (en) 2011-08-09
CA2223140A1 (en) 1996-12-12
IL149971A (en) 2010-04-29
US20020028927A1 (en) 2002-03-07
IL122251A0 (en) 1998-04-05
JP2011121970A (ja) 2011-06-23
JP4712001B2 (ja) 2011-06-29
ATE258185T1 (de) 2004-02-15
PT853627E (pt) 2004-05-31
KR100416335B1 (ko) 2004-07-27
US6184366B1 (en) 2001-02-06
EP0853627B1 (de) 2004-01-21
HUP9802662A2 (hu) 1999-05-28
US20100227835A1 (en) 2010-09-09
CN1192216A (zh) 1998-09-02

Similar Documents

Publication Publication Date Title
DK0853627T3 (da) Substituerede liposaccharider, som er egnede til behandling og forebyggelse af endotoksæmi
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
FI960780A0 (fi) Nolla intermediaarinen frekvenssivastaanotin
DE69729877D1 (de) Mycophenol bisphosponatverbindungen
BR9808491A (pt) Compostos calcilìticos
DE69414874T2 (de) Kryptographischer empfänger
ID23374A (id) Halogenopirimidin
ES1017793Y (es) Aparato refrigerador, especialmente frigorifico domestico.
DE59510131D1 (de) Imidazopyridin-azolidinone
DE69403659T2 (de) Start-stop-empfänger
FR2711810B1 (fr) Lunettes crantées.
FR2717185B1 (fr) Microfiltration de la bière.
ES1030365Y (es) Nevera portatil.
NO984083L (no) Substituerte 3-aryl-3-karboksylalkyl-glutarimider, fremgangsmÕte ved fremstilling av disse ved 4-arylo-4-cyanoheptan-dikarboksylsyrecyklisering, og anvendelse derav for fremstilling av 3-aryl-3-hydroksyalkylpiperidiner
NO960324L (no) Mottaker for selektivt anrop
FR2720751B1 (fr) Copolymère polyoléfinique greffe.
NO960796L (no) Benzotiofenonforbindelser, mellomprodukter, sammensetninger og fremgangsmåter
ES1031366Y (es) Cuna convertible.
TR199801087T2 (xx) 4,10 �- diasetoksi-2alfa-Benzoiloksi- 5 �, 20 epoksi-1- hidroksi-9- okso-19- norsiklopropa(G) taks-11- en- 13alfa-il
ES1031141Y (es) Somier de laminas oscililantes, transformables en fijas.
ITLU930002A1 (it) Ricevitore reazionato accoppiato.
NO306600B1 (no) Liposomer, anvendelige som jernkilde, samt naeringsmiddel og fremgangsmåte for fremstilling av slike liposomer
ES1031002Y (es) Atraccion de feria autotransportable.
ES1028635Y (es) Perfeccionamientos introducidos en hogares.
ES1032087Y (es) Perfeccionamientos introducidos en puertas seccionales.